Remove express-pharma-magazine
article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.

article thumbnail

Gene editing: beyond the hype

pharmaphorum

“They wanted someone who had lots of experience in drug development, was a molecular biologist, and was stubborn enough to take on CRISPR!” It has also built its own manufacturing site and launched partnerships with six big pharma companies. George Underwood is pharmaphorum’s Deep Dive magazine editor. billion in funding.